Shao-Hua Xie1,2, Giola Santoni3, Jesper Lagergren3,4. 1. School of Public Health and Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China. shaohuaxie@fjmu.edu.cn. 2. Upper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. shaohuaxie@fjmu.edu.cn. 3. Upper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. 4. School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
Abstract
BACKGROUND: Oesophageal adenocarcinoma is characterised by a strong male predominance. We aimed to test the hypothesis that menopausal hormonal therapy decreases the risk of oesophageal adenocarcinoma. METHODS: This population-based cohort study included all women who used systemic menopausal hormonal therapy (exposed) in Sweden between 2005 and 2018. For each exposed participant, five randomly selected female age-matched non-users of menopausal hormonal therapy (unexposed) were included. Cox regression provided hazard ratios (HR) with 95% confidence intervals (CI) adjusted for age, smoking-related diagnoses, Helicobacter pylori eradication, use of non-steroidal anti-inflammatory drugs/aspirin, use of statins and hysterectomy. RESULTS: The study included 296,964 users of menopausal hormonal therapy and 1,484,820 non-users. Ever-users of menopausal hormonal therapy had an overall decreased risk of oesophageal adenocarcinoma (HR 0.78, 95% CI 0.63-0.97), which remained unchanged after further adjustment for gastro-oesophageal reflux disease (HR 0.78, 95% CI 0.63-0.97) and obesity/diabetes (HR 0.79, 95% CI 0.63-0.98). Decreased HRs were indicated both in users of oestrogen only (HR 0.82, 95% CI 0.60-1.12) and oestrogen combined with progestogen (HR 0.75, 95% CI 0.56-1.00). The risk reduction was more pronounced in users younger than 60 years (HR 0.57, 95% CI 0.38-0.86). CONCLUSIONS: Menopausal hormone therapy in women may decrease the risk of oesophageal adenocarcinoma.
BACKGROUND: Oesophageal adenocarcinoma is characterised by a strong male predominance. We aimed to test the hypothesis that menopausal hormonal therapy decreases the risk of oesophageal adenocarcinoma. METHODS: This population-based cohort study included all women who used systemic menopausal hormonal therapy (exposed) in Sweden between 2005 and 2018. For each exposed participant, five randomly selected female age-matched non-users of menopausal hormonal therapy (unexposed) were included. Cox regression provided hazard ratios (HR) with 95% confidence intervals (CI) adjusted for age, smoking-related diagnoses, Helicobacter pylori eradication, use of non-steroidal anti-inflammatory drugs/aspirin, use of statins and hysterectomy. RESULTS: The study included 296,964 users of menopausal hormonal therapy and 1,484,820 non-users. Ever-users of menopausal hormonal therapy had an overall decreased risk of oesophageal adenocarcinoma (HR 0.78, 95% CI 0.63-0.97), which remained unchanged after further adjustment for gastro-oesophageal reflux disease (HR 0.78, 95% CI 0.63-0.97) and obesity/diabetes (HR 0.79, 95% CI 0.63-0.98). Decreased HRs were indicated both in users of oestrogen only (HR 0.82, 95% CI 0.60-1.12) and oestrogen combined with progestogen (HR 0.75, 95% CI 0.56-1.00). The risk reduction was more pronounced in users younger than 60 years (HR 0.57, 95% CI 0.38-0.86). CONCLUSIONS: Menopausal hormone therapy in women may decrease the risk of oesophageal adenocarcinoma.
Authors: Deirdre P Cronin-Fenton; Liam J Murray; David C Whiteman; Chris Cardwell; Penelope M Webb; Susan J Jordan; Douglas A Corley; Linda Sharp; Jesper Lagergren Journal: Eur J Cancer Date: 2010-04-22 Impact factor: 9.162
Authors: X Castellsagué; N Muñoz; E De Stefani; C G Victora; R Castelletto; P A Rolón; M J Quintana Journal: Int J Cancer Date: 1999-08-27 Impact factor: 7.396
Authors: Shao-Hua Xie; Rui Fang; Mingtao Huang; Juncheng Dai; Aaron P Thrift; Lesley A Anderson; Wong-Ho Chow; Leslie Bernstein; Marilie D Gammon; Harvey A Risch; Nicholas J Shaheen; Brian J Reid; Anna H Wu; Prasad G Iyer; Geoffrey Liu; Douglas A Corley; David C Whiteman; Carlos Caldas; Paul D Pharoah; Laura J Hardie; Rebecca C Fitzgerald; Hongbing Shen; Thomas L Vaughan; Jesper Lagergren Journal: Clin Gastroenterol Hepatol Date: 2019-11-19 Impact factor: 11.382
Authors: Úna C McMenamin; Peipei Liu; Andrew T Kunzmann; Michael B Cook; Helen G Coleman; Brian T Johnston; Marie M Cantwell; Chris R Cardwell Journal: Am J Gastroenterol Date: 2021-03-01 Impact factor: 12.045